Literature DB >> 17468348

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.

Arthur J Bergman1, Josee Cote, Bingming Yi, Thomas Marbury, Suzanne K Swan, William Smith, Keith Gottesdiener, John Wagner, Gary A Herman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17468348     DOI： 10.2337/dc06-2545

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  52 in total

1.  Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.

Authors:  Rolee Pathak; Mary Barna Bridgeman
Journal:  P T       Date:  2010-09

2.  Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.

Authors:  Himanshu Naik; Richard Czerniak; Majid Vakilynejad
Journal:  Br J Clin Pharmacol       Date:  2016-02-22       Impact factor: 4.335

3.  Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

Authors:  Gary A Herman; Goutam C Mistry; Bingming Yi; Arthur J Bergman; Amy Q Wang; Wei Zeng; Li Chen; Karen Snyder; Jon L Ruckle; Patrick J Larson; Michael J Davies; Ronald B Langdon; Keith M Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

4.  Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors:  Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal:  Clin Med Ther       Date:  2009-08-27

5.  Time of effect duration and administration interval for sitagliptin in patients with kidney failure.

Authors:  Frieder Keller; Bertram Hartmann; David Czock
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-19       Impact factor: 2.441

Review 6.  Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

7.  Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels.

Authors:  Rupinder Singh Buttar; Jasveen Batra; Jacqueline Kreimerman; Melissa Aleta; Michal L Melamed
Journal:  J Gen Intern Med       Date:  2017-07-13       Impact factor: 5.128

Review 8.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

9.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.